Author's posts
Mayo Clinic Expands Deeper Into Worksite Care With New Partner
The Mayo Clinic is partnering with employee wellness center provider Premise Health to improve healthcare at the work site.
Speculation Mounts About Walgreens Acquisition Targets
Speculation is growing that Walgreens may buy the rest of AmerisourceBergen Corp. or diagnostic testing firm LabCorp.
Philadelphia Soda Tax Cut Consumption By 1.3 Billion Ounces
A tax on sugar-sweetened beverages led to 1.3 billon-ounce decrease in beverages sold in Philadelphia, an investigation in JAMA revealed.
New Doctors Flooded With Job Offers, Mostly At Hospitals
Final-year medical resident physicians are headed for hospital employment and other locations where they will work for somebody else rather than start their careers as independent physicians, Merritt Hawkins says in a new survey.
New Doctors Flooded With Job Offers, Mostly At Hospitals
Final-year medical resident physicians are headed for hospital employment and other locations where they will work for somebody else rather than start their careers as independent physicians, Merritt Hawkins says in a new survey.
Hospital Prices Boost Bernie Sanders And Michael Bennet Medicare Plans
Lower hospital prices that Medicare pays could boost Bernie Sanders’ Medicare for All and a public option proposal authored by Sen. Michael Bennet, another Democrat running for President.
Study: Employers Pay 240% More Than Medicare For Hospital Care
Employers paid 241% on average more for hospital care than Medicare in 25 states, a RAND Corp. analysis shows.
Centene CEO: We’re Committed To Buying WellCare
Centene CEO Michael Neidorff is committed to completing the acquisition of WellCare Health Plans with the regulatory process well underway.
Centene Deal Talk Comes As Humana’s Medicaid Business Grows
Speculation Humana may be interested in acquiring Centene comes as Humana looks to grow its Medicaid business.
Insurers Brace For Pfizer’s $225K Heart Drug And Whether To Pay For It
It’s unclear whether health insurers and PBMs will cover Pfizer’s $225,000 a year drug tafamidis to treat a rare heart disease.
